# The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT

> **NCT07126782** · EARLY_PHASE1 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 10 (estimated)

## Conditions studied

- AML (Acute Myelogenous Leukemia)
- AML

## Interventions

- **BIOLOGICAL:** Ex-vivo expanded allogeneic γδ T cells

## Key facts

- **NCT ID:** NCT07126782
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-20
- **Primary completion:** 2027-12-20
- **Final completion:** 2028-07-20
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07126782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07126782, "The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07126782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*